

HNE AREA Intensive Care

Approved For: JHH ICU and HDU

OCTREOTIDE IV

Trade Name: Sandostatin

Presentation:

Indications: Octapeptide somatostatin analogue..

Indications

- Acute bleeding of oesophageal varicies
- Gastrointestinal fistulae which has not responded promptly to conventional therapy
- Other uses unlikely in ICU include Acromegaly, carcinoid tumours, VIPoma, glucagonoma

Administration: **Oesophageal varicies**

200mcg diluted to 50ml N/S. Dose: 50mcg I.V. Bolus followed by 25mcg/hr i.v.(may increase up to 50mcg/hr)for 24 hrs and review.

GIT fistulae:

Dose: 100mcg three times daily either sci or i.v (may increase to 200mcg three times daily).
N.B. SCI preferred for intermittent dosage to exploit delayed-absorption kinetics thus providing prolonged activity.

Dose

Precautions Use within 8 hours of preparation. Infusion fluid must be used within 24hrs.

Adverse effects: pain, redness & swelling at SCI site. Impaired glucose tolerance, liver dysfunction including acute hepatitis & hyperbilirubinaemia, mild bradycardia. Abdominal bloating, pain,flatulence,diarrhoea.

Compatibilities: Unknown

Created: 01-Feb-04 by Dr K Havill Reviewed: 01-Feb-05 by Dr K Havill Guideline to be reviewed before : 01-Jun-10

These guidelines are intended for and to be used only by experienced critical care staff under direct supervision of Hunter Health Area Intensive Care Specialists in designated Hunter Health Area Critical Care Areas. The Authors will not be responsible for inappropriate use of these guidelines